Faculty Profile


Hatim Hassan
Section of Nephrology
Assistant Professor of Medicine
hhassan@medicine.bsd.uchicago.edu
Referring Physician Access Line: 1-877-DOM-2730

Academic Interests

Dr. Hassan’s research focuses on elucidating the molecular mechanisms regulating intestinal oxalate transport, with a special emphasis on the gut epithelial transporter SLC26A6, by different neurohumoral factors and gut microbiome, and how this regulation might pertain to the risk of hyperoxalemia, hyperoxaluria, and calcium oxalate kidney stones. Seventy-80% of kidney stones are composed of calcium oxalate, and small increases in urinary oxalate enhance the risk of stone development. The mammalian intestine plays a crucial role in oxalate homeostasis. Intestinal oxalate secretion mediated by the key oxalate transporter SLC26A6 plays an essential role in limiting net intestinal absorption of dietary oxalate, thereby preventing hyperoxalemia, hyperoxaluria and calcium oxalate kidney stones. Dr. Hassan had previously shown that cholinergic, purinergic, and adenosinergic signaling inhibits oxalate transport by human intestinal epithelial cells by reducing SLC26A6 surface membrane expression. Dr. Hassan’s current projects include: Potential roles of proinflammatory cytokines and gut microbiome in the pathogenesis of obesity - and IBD-associated hyperoxaluria. In addition, Dr. Hassan’s lab is evaluating the role of factors secreted by the probiotic bacterium Oxalobacter formigenes (Of) in reducing urinary oxalate excretion in hyperoxaluric mice by stimulating colonic oxalate secretion. In this regard the Hassan lab has successfully identified small peptides derived from a family of signaling proteins as the Of-derived factors. These findings indicate that small peptides can be developed therapeutically and a startup company (Oxalo Therapeutic) has been recently formed to facilitate the achievement of the long-term goal of developing a peptide-based oral drug for the prevention and/or treatment of hyperoxalemia, hyperoxaluria, and calcium oxalate kidney stones.
 

Clinical Interests

Fluid and electrolyte and acid-base disorders, kidney stones, and acute renal failure.
 

Publications

  • Hassan HA, Cheng M, and Aronson PS. Cholinergic signaling inhibits oxalate transport by human intestinal T84 cells. American Journal of Physiology Cell Physiology 302: C46-58, 2012. This manuscript is highlighted by an accompanying editorial commentary.
  • Amin R, Sharma S, Ratakonda S, and Hassan HA. Extracellular nucleotides inhibit oxalate transport by human intestinal Caco-2-BBe cells through PKC-delta activation. American Journal of Physiology Cell Physiology 305: C78-89, 2013.
  • Amin R, Asplin J, Jung D, Bashir M, Alshaikh A, Ratakonda S, Sharma S, Jeon S, Granja I, Matern D, and Hassan H. Reduced active transcellular intestinal oxalate secretion contributes to the pathogenesis of obesity-associated hyperoxaluria. Kidney international 93: 1098-1107, 2018. This manuscript is highlighted by an accompanying editorial commentary.
  • Jung D, Alshaikh A, Ratakonda S, Bashir M, Amin MR, Jeon S, Stevens J, Sharma S, Ahmed W, Musch M, and Hassan H. Adenosinergic Signaling Inhibits Oxalate Transport by Human Intestinal Caco2-BBE Cells Through the A2B Adenosine Receptor. American Journal of Physiology Cell Physiology, 2018.
  • Arvans D, Jung YC, Antonopoulos D, Koval J, Granja I, Bashir M, Karrar E, Roy-Chowdhury J, Musch M, Asplin J, Chang E, and Hassan H. Oxalobacter formigenes-Derived Bioactive Factors Stimulate Oxalate Transport by Intestinal Epithelial Cells. Journal of the American Society of Nephrology : JASN 28: 876-887, 2017. This article was covered by a Press Release [covered by 15 media outlets, one radio interview (www.infobioquimica.org), 3 blogs, and highlighted by Nature Reviews Nephrology].
For a complete list of publications click here:

Training

  • MD, 1994, University of Khartoum Medical School, Khartoum, Sudan,
  • Residency, 1996, Cairo University Hospitals, Egypt, Internal Medicine
  • Fellowship, 1999, St. Louis University, Nephrology
  • Residency, 2001, St. Louis University, Internal Medicine
  • Fellowship, 2005, Yale University School of Medicine, Nephrology
  • PhD, 2007, Yale University, New Haven, CT, Investigative Medicine